Alexander Zemchenkov

Dr. Alexander Zemchenkov

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2023 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
BNBrendon L Neuen
Brendon L Neuen
ABAminu K Bello
Aminu K Bello
ALAdeera Levin
Adeera Levin
MLMeaghan Lunney
Meaghan Lunney
MOMohamed A Osman
Mohamed A Osman
DJDavid Johnson
David Johnson
National strategies for addressing chronic kidney disease (CKD) are crucial to improving kidney health. We sought to describe country-level variations in non-communicable disease (NCD) strategies and CKD-specific policies across different regions and income levels worldwide. The International Society of Nephrology Global Kidney Health Atlas (GKHA) was a multinational cross-sectional survey conducted between July and October 2018. Responses from key opinion leaders in each country regarding national NCD strategies, the presence and scope of CKD-specific policies, and government recognition of CKD as a health priority were described overall and according to region and income level. 160 countries participated in the GKHA survey, comprising 97.8% of the world’s population. Seventy-four (47%) countries had an established national NCD strategy, and 53 (34%) countries reported the existence of CKD-specific policies, with substantial variation across regions and income levels. Where CKD-specific policies existed, non-dialysis CKD care was variably addressed. 79 (51%) countries identified government recognition of CKD as a health priority. Low- and low-middle income countries were less likely to have strategies and policies for addressing CKD and have governments which recognise it as a health priority. The existence of CKD-specific policies, and a national NCD strategy more broadly, varied substantially across different regions around the world but was overall suboptimal, with major discrepancies between the burden of CKD in many countries and governmental recognition of CKD as a health priority. Greater recognition of CKD within national health policy is critical to improving kidney healthcare globally.

27 October 2016 in Hemodialysis International
Verified
Journal Article
Closed access
PDF file
BBBoris Bikbov
Boris Bikbov
BBBrian Bieber
Brian Bieber
AAAnton Andrusev
Anton Andrusev
NTNatalia Tomilina
Natalia Tomilina
AZAlexander Zemchenkov
Alexander Zemchenkov
RPRonald Pisoni
Ronald Pisoni

7 July 2016 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
AZAlexander Zemchenkov
Alexander Zemchenkov
IKIrina N. Konakova
Irina N. Konakova
Renal replacement therapy (RRT) is growing by 10 % per year in Russia, but pre-dialysis care which can retard CKD progression and delay the start of RRT remains limited. We evaluate the effect of Essential Amino Acids and Keto-analogues (EAA/KA) on CKD progression. The effect of low protein diet (LPD), supplemented by EAA/KA, on GFR slope changes between first and second treatment period (five sequential visits per period) in 96 patients withs CKD Stage 3B-5 was compared to GFR slope changes in the control group of 96 patients, randomly selected from matched (by gender, age, diagnosis and CKD Stage) cohort of 320 patients from the city Registry. The mean baseline eGFR was 23 ± 9 ml/min/1.73 m2; 29 % had CKD3B, 45 % - CKD4, 26 % - CKD5. The rate of eGFR decline changed from −2.71 ± 2.38 to −2.01 ± 2.26 ml/min/1.73 m2 per year in the treatment group and from −2.18 ± 2.01 to −2.04 ± 2.18 ml/min/1.73 m2 per year in the control group. Only in the treatment group the difference was significant (p = 0.04 and p = 0.6). Standardized effect size for intervention was significant in treatment group: −0.3 (of pooled SD), 95 % CI −0.58 ÷ −0.02 and non-significant in control group: −0.07 (−0.35 ÷ +0.22). The univariate and multivariate analysis of EAA/KA therapy effect demonstrated that it was probably more effective in patients of older age, with higher time-averaged proteinuria (PU), lower phosphate level, in patients with glomerular v. interstitial diseases, and in females. Only the latter factor was significant at pre-specified level (<0.05). LPD combined with EAA/KA supplementation lead to the decrease of the CKD progression both in well-designed clinical study and in real nephrology practice in wide variety diseases and settings. Registry data can be helpful to reveal patients with optimal chances for beneficial effect of LPD supplemented by EAA/KA. ISRCTN28190556 06/05/2016.

22 March 2025 in Nephrology and Dialysis
Verified
Journal Article
Open access
PDF file
KVK. A. Vishnevskii
K. A. Vishnevskii
EPE. V. Parshina
E. V. Parshina
AZAlexander Zemchenkov
Alexander Zemchenkov
RGR. P. Gerasemchuk
R. P. Gerasemchuk
IRI. A. Reutsky
I. A. Reutsky
ABA. N. Belskikh
A. N. Belskikh
A direct comparison of the long-term effectiveness of combined interventions in controlled studies is often challenging, if not infeasible due to ethical concerns, due to ethical concerns, including the reluctance to withhold potentially beneficial treatments. This gap can be addressed through pragmatic research or the analysis of large prospectively collected datasets, such as registers. In addition providing valuable outcome assessments, these datasets enable the formation of matched groups for comparison in interventional studies, which, under certain conditions, may serve as a form of quasi-randomization.This study analyzes data from the renal replacement therapy registry in a large city, covering the period from the transition of dialysis to the compulsory medical insurance system in 2009, ensuring accurate tracking of therapy initiation and outcomes untill the COVID-19 pandemic, which disrupted the stable organization and outcomes of dialysis. The analysis focuses on factors associated to patient survival, particularly those directly related to dialysis and chronic kidney disease syndromes during this period.The overall five-year survival rate was 60.4%±1.5%. Factors at dialysis initiation associated with adverse outcomes included: age (+1% risk increase per year of age), the underlying disease diagnosis, baseline residual GFR below 5.3 ml/min/1.73 m2 (+41%), or below 3.6 ml/ min/1.73 m2 (+55%), phosphatemia above 1.78 mmol/L (+58%) or below 1,13 mmol/ L (+38%); calcemia outside the target range (+57% risk for low levels, +120% risk for high levels); natremia (above 141 mmol/L (+62%); albuminemia (below 36 g/L (+22%); interdialytic weight gain (+23% for each 1% of body weight increase), and urgent of dialysis initiation. During maintenance dialysis (indicator period – 3th-15th months) adverse outcomes were associated with phosphatemia above 1.78 mmol/l (68% risk increase), calcemia above 2.5 mmol/L (+122% risk) and their interaction, as well as ultrafiltration rate above 8 ml/hour/kg (165% risk increase and higher for more fast ultrafiltration). Additional risk factors include worsening hyperphosphatemia (+72%), deviation in calcemia from target range (+16% risk for downward shifts, +43% risk for upwards shifts) and ultrafiltration rate exceeding 10 ml/hour/kg (+21%). Notably, anemia correction indicators and their trends, under current favorable treatment practice, were not identified as significant risk factors.Detailed patient data will facilitate the evaluation of intervention impacts on dialysis outcomes by enabling comparison matched historical cohorts.

27 June 2018 in Russian Journal of Transplantology and Artificial Organs
Verified
Journal Article
Open access
PDF file
AZAlexander Zemchenkov
Alexander Zemchenkov
RGR. P. Gerasimchuk
R. P. Gerasimchuk
ASA. B. Sabodash
A. B. Sabodash
KVK. A. Vishnevskii
K. A. Vishnevskii
GZG. A. Zemchenkov
G. A. Zemchenkov
ARAleksandr Rumyantsev
Aleksandr Rumyantsev
Цель. Оптимальное время начала лечения гемодиализом (ГД) остается неопределенным. Создание шкалы для оценки рисков для пациента, начинающего диализ, поможет в принятии решения о сроках его начала. Методы. По данным регистра пациентов на заместительной почечной терапии проанализированы результаты лечения 1856 пациентов, начавших диализ в 2009–2016 гг. Случайным образом их разделили в соотношении 1:1 на группу разработки и группу подтверждения для создания прогностической шкалы оценки вероятности летального исхода при лечении программным гемодиализом (шкала START). При этом учитывали модифицируемые и немодифицируемые факторы риска. В серии регрессионных моделей с одной переменной в группе разработки шкалы мы оценивали риски смерти, связанные с доступными для анализа модифицируемыми и немодифицируемыми параметрами. Среди них значимыми оказались возраст, расчетная скорость клубочковой фильтрации (рСКФ), уровни фосфатов, общего кальция, гемоглобина, индекс коморбидности Чарлсон, наличие сахарного диабета, экстренность старта диализа. Пол, уровни натрия, калия, артериального давления не оказали влияния на выживаемость. Близкие по величине риски были преобразованы в баллы шкалы. Результаты. Шкала START продемонстрировала высокую предсказательную ценность в отношении риска смерти: AUC 0,82 (95% ДИ 0,79–0,85) для группы разработки шкалы и 0,79 (95% ДИ 0,74–0,84) для группы подтверждения (для обеих p < 0,001). Для точки отсечения 7–8 баллов чувствительность метода составила 81,1%, специфичность 69,9% для группы разработки и 78,9 и 67,9% соответственно – для группы подтверждения. Мы подтвердили близкие значения выживаемости пациентов в обеих группах для низких, средних и высоких значений шкалы START. Различия в выживаемости для подгрупп с тремя уровнями шкалы были близкими для групп разработки и подтверждения: критерий Wilcoxon = 8,78 (p = 0,02) vs 15,31 (p < 0,001) при сравнении выживаемости подгрупп низких и средних величин шкалы и 25,18 (p < 0,001) vs 39,21 (p < 0,001) при сравнении выживаемости подгрупп средних и высоких величин шкалы. Заключение. Разработанная шкала START, включающая модифицируемые факторы риска, продемонстрировала хорошую предсказательную ценность в отношении 5-летней летальности и может использоваться при принятии решения о времени старта диализа.

1 January 2018 in Nephrology (Saint-Petersburg)
Verified
Journal Article
Open access
PDF file
KVK. A. Vishnevskii
K. A. Vishnevskii
AZAlexander Zemchenkov
Alexander Zemchenkov
RGR. P. Gerasimchuk
R. P. Gerasimchuk
ARAleksandr Rumyantsev
Aleksandr Rumyantsev
ASA. V. Smirnov
A. V. Smirnov
PMP. V. Maryutin
P. V. Maryutin
У большинства пациентов, получающих программный гемодиализ, наблюдаются минерально-костные нарушения, из которых наиболее распространённым является вторичный гиперпаратиреоз. Для коррекции этого жизнеугрожающего осложнения хронической болезни почек в последнее десятилетие разработаны и введены в клиническую практику ряд новых препаратов, таких как парикальцитол, цинакалцет и некоторые фосфат-связывающие медикаменты. Ввиду увеличения государственных затрат на данную терапию во многих странах, в том числе и в России, были проведены ряд фармакоэкономических исследований, призванных определить целесообразность назначения определенных препаратов по критерию «затраты–эффективность». В данном обзоре выполнен краткий анализ методов оценки рентабельности лекарственных препаратов и рассмотрены результаты недавних исследований, посвященных оценке экономической эффективности лечения МКН–ХБП.